Form 4: Iradimed Corp Insider Sells Shares Under 10b5-1 Plan

Iradimed Corp CEO Roger E. Susi sold a total of 6,486 shares of common stock across multiple transactions on May 11th and 12th, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Roger E. Susi, CEO, President, Chairman, Director, and 10% owner of Iradimed Corporation, executed a series of stock sales on May 11 and May 12, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on November 5, 2025, which is designed to satisfy affirmative defense conditions for insider trading.
• A total of 6,486 shares of common stock were sold across these transactions.
• The sales occurred at weighted average prices ranging from $83.66 to $86.00.
• Following these transactions, Susi's direct and indirect beneficial ownership of Iradimed Corp common stock is detailed, with significant holdings remaining through various trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves insider selling, the transactions were conducted under a pre-established Rule 10b5-1 plan, mitigating concerns about opportunistic trading.

Negatives

• Insider selling activity, even if conducted under a 10b5-1 plan, can sometimes be perceived negatively by the market.
• The sales represent a reduction in direct beneficial ownership by a key executive.

Risks

• The filing does not explicitly mention any new or emerging risks.
• The primary risk associated with this type of filing is the potential market interpretation of insider selling, regardless of the plan's compliance with Rule 10b5-1.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It is a report of past transactions.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The use of a Rule 10b5-1 plan by a CEO of a medical device company like Iradimed is common practice to diversify holdings or manage personal finances without creating the appearance of trading on material non-public information.

Stakeholder Impact

• Shareholders: May interpret insider selling, even under a 10b5-1 plan, as a signal of reduced confidence, though the plan's existence aims to prevent this. Significant beneficial ownership remains with the reporting person and related trusts.
• Employees: No direct impact mentioned.
• Creditors: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Customers: No direct impact mentioned.

Next Steps

• Continued monitoring of insider transactions for any further sales or purchases.
• Review of future Iradimed Corp financial reports and strategic updates.

Key Dates

Keywords

Iradimed Corp, IRMD, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Roger E. Susi, Beneficial Ownership, Securities Exchange Act